Phase II evaluation of 4'-(9-acridinylamino)-methanesulfon-m-anisidide (m-AMSA) in patients with gastric adenocarcinoma.
作者信息
Sordillo P P, Magill G B, Gralla R J, Kelsen D P
出版信息
Am J Clin Oncol. 1982 Jun;5(3):273-5. doi: 10.1097/00000421-198206000-00006.
Abstract
A phase II study of m-AMSA in patients with gastric adenocarcinoma was conducted. Twenty-three patients received m-AMSA, 90-120 mg/m2, every 3 weeks. There were no major responses among 20 evaluable patients, although one patient experienced a minor response. Depression of the white blood count was the most prominent toxicity. m-AMSA has little activity in patients with gastric adenocarcinoma.
摘要
Zotero 插件